Literatur
- Hummel et al. 2019 Physiologic and histopathologic effects of targeted lung denervation in an animal model J Appl Physiol 126:67–76
- Valipour et al. 2020 Two-year outcomes for the double-blind, randomized, sham-controlled study of targeted lung denervation in patients with moderate to severe COPD: AIRFLOW-2 Int J Chron Obstruct Pulmon 15:2807–2816
- Pavord et al. 2017 Mepolizumab for eosinophilic chronic obstructive pulmonary disease N Engl J Med 377(17): 1613–1629
- Mayse et al. 2020 Targeted lung denervation in sheep: durability of denervation and long-term histologic effects on bronchial wall and peribronchial structures Respir Res 21:117
- Zhang et al. 2018 A systematic review of how patients value COPD outcomes Eur Respir J 19;52(1)
- Ihenacho et al. 2020 Economic burden of chronic obstructive pulmonary disease (COPD): A systematic literature review Int J Chron Obstruct Pulmon Dis 26;15: 439–460
- Dalal et al. 2011 Costs of COPD exacerbations in the emergency department and inpatient setting Respir Med 105(3):454–60
- Dalal et al. 2015 Impact of COPD exacerbation frequency on costs for a managed care population J Manag Care Spec Pharm 21(7): 575–83
- Patel et al. 2018 COPD affects worker productivity and health care costs Int J COPD 13:2301–2311
- Lipson et al. 2018 Once-daily single-inhaler versus dual therapy in patients with COPD N Engl J Med 378(18): 1671–1680
- Rabe et al. 2020 Triple inhaled therapy and two glucocorticoid doses in moderate-to-very severe COPD N Engl J Med 383(1):35–48
- Donaldson et al. 2002 Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease Thorax 57(10):847–52
- Halpin et al. 2017 Effect of a single exacerbation on decline in lung function in COPD Respir Med 128: 85–91
- Dransfield et al. 2017 Acute exacerbations and lung function loss in smokers with and without Chronic Obstructive Pulmonary Disease Am J Respir Crit Care Med 195(3): 324–330
- Seemungal et al. 1998 Effect of exacerbation on quality of life with chronic obstructive pulmonary disease Am J Respir Crit Care Med 157:1418–22
- Westerik et al. 2017 Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD Respir Res 18(1):31
- Soler-Cataluna et al. 2005 Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease Thorax 60(11):925–31
- Rothnie et al. 2018 Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease Am J Respir Crit Care Med 198(4):464–471
- Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease 2021 Report
- Hurst et al. 2020 Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life Eur J Intern Med 73:1–6
- Pison et al. 2021 Safety of denervation following targeted lung denervation therapy for COPD AIRFLOW-1 3-year outcomes Respir Res 22(1): 62
- Hartman JE, Conway F, Degano B, Augustijn SWS, Herth FJF, Mayr A, Chacaroun S, Tonkin J, Valipour A, Slebos DJ. Rate of lung function decline slows in the 3 years after targeted lung denervation in COPD. Respir Med 2021; 188: 106604.
- Khakban et al. 2017 The projected Epidemic of Chronic Obstructive Pulmonary Disease Hospitalizations over the Next 15 Years. A Population-based Perspective Am J Respir Crit Care Med 2016;195(3):1–5.
- Canning BJ 2006 Reflex regulation of airway smooth muscle tone J Appl Physiol 101:971–985.
- Valipour A et al. 2018 Long-term safety of bilateral targeted lung denervation in patients with COPD Int J Chron Obstruct Pulmon Dis 13:2163–2172.
- Valipour A et al. 2019 Safety and dose study of targeted lung denervation in moderate/severe COPD patients Respiration 98:329–339.
- Slebos DJ et al. 2019 Safety and adverse events after targeted lung denervation for symptomatic moderate to severe chronic obstructive pulmonary disease (AIRFLOW). A multicenter randomized controlled clinical trial Am J Respir Crit Care 200:1477–1486.
Zu häufigen potenziellen Risiken im Zusammenhang mit dem TLD-Verfahren zählen u. a. Verschlimmerung der COPD-Symptome (Kurzatmigkeit, vermehrtes Husten, COPD-Exazerbationen), Abhusten von blutigem Schleim, Schluckbeschwerden, Schmerzen in der Brust, Magenverstimmung oder Völlegefühl, Verdauungsstörungen und Fieber.
Das dNerva®-Lungendenervierungssystem ist ein Prüfprodukt in den USA und besitzt die CE-Kennzeichnung.